Why Contineum Therapeutics, Inc.’s (CTNM) Stock Is Up 13.17%
As of Wednesday, September 30, Contineum Therapeutics, Inc.’s CTNM share price has surged by 13.17%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Commentary & Analysis
Why Contineum Therapeutics, Inc.’s (CTNM) Stock Is Up 11.00%
As of Wednesday, September 30, Contineum Therapeutics, Inc.’s CTNM share price has surged by 11.00%, which has investors questioning if this is right time to sell.Tudor Pop
Why Contineum Therapeutics, Inc.’s (CTNM) Stock Is Down 5.76%
As of Thursday, September 24, Contineum Therapeutics, Inc.’s CTNM share price has dipped by 5.76%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Contineum Therapeutics, Inc.’s (CTNM) Stock Is Down 6.58%
As of Tuesday, September 15, Contineum Therapeutics, Inc.’s CTNM share price has dipped by 6.58%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Contineum Therapeutics, Inc.’s (CTNM) Stock Is Up 5.79%
As of Wednesday, August 19, Contineum Therapeutics, Inc.’s CTNM share price has surged by 5.79%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | CTNM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $503.4 | $519.2 | 37% |
|
| Shares Out (Mil) | 37.5 | 42.8 | 41% |
|
| Institutional Ownership | 98.3% | 82.8% | 78% |
|
| Float (Mil) | 27.7 | 44.4 | 34% |
|
| Beta | 0.74 | 0.71 | 44% |
|
| Avg Daily Volume (000s) | 860 | 394 | 67% |
|
| Price Change (52-week) |
10.0% | 60.2% | 62% |
|
| Growth | CTNM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | na | (2.0%) | na |
|
| EPS (5yr) | na | 15.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.454) | ($1.713) | ($1.916) | |
| Month Ago EPS | ($0.454) | ($1.556) | ($1.797) | |
| # Rev Up | 2 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.429) | ($1.647) | ($1.814) | |
| Year/Year Chg | 12.4% | (20.9%) | (17.2%) | |
| Financials | CTNM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($58) | ($11) | 15% |
|
| EPS (TTM) | ($1.720) | ($0.700) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($53) | ($7) | 9% |
|
| Net Cash Flow (TTM) (Mil) | ($6) | $6 | 33% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $6 | 23% |
|
| Enterprise Value (Q1) (Mil) | $369 | $494 | 31% |
|
| Valuation | CTNM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.10 | 2.31 | 54% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CTNM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (26.6%) | (22.2%) | 18% |
|
| ROE | (28.0%) | (21.4%) | 21% |
|
| Liabilities to Assets | 4.3% | 32.8% | 2% |
|
| F-Score | 3 | 3 | 18% |
|
Passing Stock Screens
As of 10/9/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Lowest 30 Down
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 3.0% |
| +/- S&P 500: | -4.5 |
FACTOR STRATEGY
Est Rev: Down 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.3% |
| +/- S&P 500: | -5.2 |
